Literature DB >> 2096009

Glucose metabolism in quinine-treated patients with uncomplicated falciparum malaria.

T M Davis1, S Pukrittayakamee, W Supanaranond, S Looareesuwan, S Krishna, B Nagachinta, R C Turner, N J White.   

Abstract

To investigate host and drug effects on glucose metabolism in acute falciparum malaria, 10 previously untreated, fasting Thai males with uncomplicated infections were given a 2-h intravenous glucose infusion (5 mg/kg ideal body weight min) with an infusion of quinine dihydrochloride (10 mg/kg body weight) during the second hour. Eight patients were restudied in convalescence. Fasting plasma glucose (mean +/- SD) and insulin (geometric mean (-SD to + SD] were higher during acute illness (5.5 +/- 1.0 mmol/l and 6.2 (5.0-7.7) mU/l) than in convalescence (4.2 +/- 0.25 mmol/l and 3.7 (2.1-6.7) mU/l; P less than 0.001 and P = 0.058 respectively). After 1 h, both plasma glucose (9.3 +/- 1.4 vs 7.5 +/- 0.8 mmol/l, P less than 0.001) and insulin (21.2 (13.8-32.5) vs 15.2 (11.2-20.8) mU/l, P = 0.089) remained higher during acute illness; mathematical model (CIGMA) assessment of these values indicated lower tissue insulin sensitivity on admission (97% (71-134] than in convalescence (139% (109-178), P less than 0.025) but normal beta-cell function on both occasions. Two-hour plasma glucose (9.5 +/- 2.0 mmol/l) and insulin (81.8 (51.5-129.9) mU/l) concentrations during acute illness were also significantly higher than in convalescence (7.2 +/- 1.2 mmol/l and 40.1 (23.5-68.4) mU/l, P less than or equal to 0.025) despite similar end-infusion free plasma quinine concentrations (P greater than 0.5). Basal plasma free fatty acid concentrations were increased in acute illness (0.68 +/- 0.24 vs 0.21 +/- 0.12 mmol/l, P less than 0.001) but fell to low levels at 2 h in both studies. These data suggest tissue insulin resistance and augmented quinine-stimulated insulin secretion in acute falciparum malaria, factors which are likely to influence the clinical situation in which malaria-associated hypoglycaemia occurs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2096009     DOI: 10.1111/j.1365-2265.1990.tb03911.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

Review 1.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

2.  Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria.

Authors:  K Silamut; P Molunto; M Ho; T M Davis; N J White
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 3.  Cachexia in malaria and heart failure: therapeutic considerations in clinical practice.

Authors:  M E Onwuamaegbu; M Henein; A J Coats
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

4.  Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria.

Authors:  Harin Karunajeewa; Chiv Lim; Te-Yu Hung; Kenneth F Ilett; Mey Bouth Denis; Doung Socheat; Timothy M E Davis
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 5.  Dysglycaemias and fluoroquinolones.

Authors:  Roshan J Lewis; John F Mohr
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly.

Authors:  J R Dyer; T M Davis; C Giele; T Annus; P Garcia-Webb; J Robson
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

7.  Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2.

Authors:  Paul Oranje; Robin Gouka; Lindsey Burggraaff; Mario Vermeer; Clément Chalet; Guus Duchateau; Pieter van der Pijl; Marian Geldof; Niels de Roo; Fenja Clauwaert; Toon Vanpaeschen; Johan Nicolaï; Tom de Bruyn; Pieter Annaert; Adriaan P IJzerman; Gerard J P van Westen
Journal:  Pharmacol Res Perspect       Date:  2019-07-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.